USFDA Warning: Intas Pharma Manufacturing Lapses

A USFDA warning letter is a serious matter, indicating substantial violations of regulations.

December 10, 2023

269

Warning Letter Sign FDA USFDA — Warning Letter

Table of Contents

Last Updated on October 10, 2024 by The Health Master

USFDA Warning

The pharmaceutical industry is under scrutiny as the US Food and Drug Administration (USFDA) issues a USFDA warning letter to Intas Pharmaceuticals.

In the complex world of pharmaceuticals, adherence to stringent regulations is paramount.

Follow us on WhtasApp Channel

Intas Pharmaceuticals, a key player in the industry, faces a significant challenge as the USFDA raises concerns about its manufacturing practices.

Let’s delve into the details of the manufacturing lapses at the Ahmedabad-based plant and the implications for the company.

USFDA Warning Letter

A USFDA warning letter is a serious matter, indicating substantial violations of regulations.

This letter, addressed to Intas Pharmaceuticals‘ CEO and MD Nimish Chudgar, highlights critical lapses observed during the inspection conducted from May 1-12, 2023.

Manufacturing Lapses at Intas

The Matoda-Sanand facility in Ahmedabad has come under scrutiny for various manufacturing lapses, notably in violation of current good manufacturing practice (CGMP) regulations.

These lapses raise questions about the quality and safety of Intas Pharmaceuticals‘ drug products.

Click for more articles on USFDA

Inspection Details

The inspection dates, May 1-12, 2023, are crucial.

During this period, the USFDA identified and documented specific issues that are outlined in the USFDA warning letter.

CGMP Violations

The USFDA warning letter emphasizes significant violations of CGMP regulations related to finished pharmaceuticals.

The non-conformity of methods, facilities, and controls poses a serious risk of adulteration to Intas Pharmaceuticals‘ drug products.

Click for more on Warning letters

Quality Assurance and Production Oversight

A major concern highlighted in the letter is the failure of the Quality Assurance (QA) and production departments to provide adequate oversight.

This lapse jeopardizes the reliability of data related to the quality of finished drug products.

Manipulation of Inspection Records

A startling revelation from the USFDA is the manipulation of visual inspection records since 2021.

Visual inspectors manipulated particle and defect counts to keep finished product batches within acceptable limits, raising questions about the integrity of the inspection process.

Click for Guidance documents for industry

Inadequate Investigation Procedures

The company’s failure to thoroughly investigate discrepancies or failures of batches further compounds the issue.

The USFDA underscores the importance of addressing any unexplained discrepancy promptly.

Lack of Written Procedures

Intas Pharmaceuticals also faces criticism for its failure to establish adequate written procedures for production and process controls.

This deficiency undermines the assurance of drug product identity, strength, purity, and quality.

Microbiological Contamination Concerns

The USFDA points out the company’s failure to establish and follow written procedures to prevent microbiological contamination of drug products.

This lapse poses additional risks to the safety and efficacy of Intas Pharmaceuticals‘ products.

Repeat Violations

Alarmingly, the USFDA warning letter reveals that similar CGMP observations were cited in a previous inspection in 2019.

The recurrence of these failures raises concerns about the effectiveness of executive management oversight.

Executive Management Oversight

The USFDA asserts that repeated failures demonstrate inadequate executive management oversight.

This raises questions about the overall effectiveness of Intas Pharmaceuticals‘ quality system in compliance with CGMP.

Also read: Understanding GMP, cGMP, and WHO-GMP

Corrective Actions Required

The letter concludes with a directive to correct violations promptly.

Failure to do so may result in the withholding of approval for new applications or supplements listing Intas Pharmaceuticals as a drug manufacturer.

Potential Consequences for Intas

The potential consequences of failing to address violations promptly are severe.

Withholding approval and continued refusal of article admission by the USFDA could have far-reaching implications for Intas Pharmaceuticals.

Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.

FAQs

What is a USFDA warning letter?
- A USFDA warning letter is issued when a pharmaceutical manufacturer is found to significantly violate regulations, indicating serious lapses in compliance.
Why is executive management oversight crucial?
- Executive management oversight ensures the effectiveness of a company’s quality system. Inadequate oversight can lead to repeated failures and regulatory issues.
What are the potential consequences of a USFDA warning letter?
- Consequences include withholding approval for new applications and the USFDA continuing to refuse admission of articles manufactured at the plant.
How does microbiological contamination impact drug products?
- Microbiological contamination poses risks to the safety and efficacy of drug products, compromising their quality.
Why is prompt corrective action essential?
- Prompt corrective action is crucial to address violations swiftly and avoid more severe consequences, such as withholding approval for new applications.